Latest Health News

Uscom Limited reported a 27% drop in cash reserves for Q1 2025, driven by declining revenue and rising costs, while preparing to sell its main business unit to stabilize finances.

Saunders International anticipates a weaker first half in FY26 amid ongoing operational challenges but gains momentum with major contracts and strategic expansion into New South Wales.

Vulcan Steel reported a sharp profit decline in FY25 amid tough market conditions but strengthened its balance sheet and expanded into roofing with a major acquisition. Leadership changes set the stage for renewed growth.

Echelon Resources reported a solid quarter with production gains at Maari and Mahato fields, supported by new wells and a strategic gas sales agreement, while maintaining shareholder returns through dividends.

Cobram Estate Olives Limited has reported a record-breaking FY2025, driven by strong sales growth in Australia and the USA, alongside a $178 million equity raise to accelerate its Californian olive grove expansion.

Carnegie Clean Energy marked steady progress in Q3 2025, hitting key manufacturing milestones for its CETO wave energy system in Spain, securing €4 million in EU funding, and raising $2.1 million from shareholders to fuel commercialisation efforts.

Otto Energy reported an 11% rise in oil production and a solid US$2 million net operating cash inflow in Q3 2025, alongside key executive and board changes.

GWA reported modest revenue and earnings growth in FY25, driven by strong performance in Australia and the UK despite a tough New Zealand market. The company also initiated a $30 million on-market share buyback and increased its fully franked dividend.

Micro-X Ltd has secured its largest-ever $3.3 million Rover Plus order from Malaysia’s Ministry of Health and is progressing critical Head CT imaging trials, supported by a $4.4 million government grant.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.

Elixinol Wellness reported steady Q3 revenue with a notable 300bps gross margin improvement, driven by e-commerce and core brands, while executing cost reduction initiatives supported by a $2.5 million capital raise.